Government of Western Australia
North Metropolitan Health Service
Women and Newborn Health Service

ADULT MEDICATION GUIDELINE	
Lidocaine (Lignocaine)	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding

Restrictions

(5% Transdermal Patch; 10% Ampoule; 2% Vial): Formulary: Restricted

Other: Formulary: Unrestricted

HIGH RISK Medication

Medication Class

Local anaesthetic; antiarrhythmic

Presentation

Lidocaine Only Products	
Form	**Strength**
Ampoule	200 mg/20 mL (1%)
Ampoule	50 mg/5 mL (1%)
Ampoule	100 mg/5 mL (2%)
Gel (Sterile Catheter Lubricant Syringe)	20 mg/ mL (2%)
Viscous Liquid (Xylocaine® Viscous)	20 mg/ mL (2%)
Gel	22 mg/ g (2%)
Ampoule (Xylocaine® Theatre Pack)	400 mg/20 mL (2%)

Transdermal Patch (Versatis®)	5%
Ointment	50 mg/ g (5%)
Spray	100 mg/ mL (10%)
Combination Products	
Form	**Active Ingredients & Strength**
Infusion Bag	Lidocaine 0.4% in Glucose 5%
Ampoule	Lidocaine 1% with Adrenaline 1:100 000
Vial	Lidocaine 2% with Adrenaline 1:200 000
Cartridge	Lidocaine 2% with Adrenaline 1:80 000
Ointment	Lidocaine 2% in White Soft Paraffin
Cream (Numit®, Emla®)	Lidocaine 2.5% with Prilocaine 2.5% (5 g, 30 g)
Patch (Emla®)	Lidocaine 2.5% with Prilocaine 2.5%
Spray (Cophenylcaine Forte®)	Lidocaine 5% with Phenylephrine 0.5%

Storage

Store at room temperature, below 25°C

5% Transdermal Patch (Versatis®): Once sachet opened, keep sealed & use contents within 14 days.

Dose

Refer to KEMH Clinical Guidelines **for appropriate dose regimes (links below)**

Localised neuropathic pain or post-herpetic neuralgia

Transdermal (5% patch):

Apply up to 3 patches at the same time to the painful area. Wear for up to 12 hours, followed by a patch-free interval of at least 12 hours.

For post-herpetic neuralgia, apply *after* shingles rash has healed.

Administration

Refer to KEMH Clinical Guidelines **for appropriate administration regimes (links below)**

Transdermal:

Remove patch from pack and remove gel liner then immediately apply to clean, dry, non-irritated skin on the painful area; patches may be cut to fit area.

While wearing the patches, do not allow them to come in contact with water or any heat source (e.g. heat pads, electric blankets).

Dispose of patches by folding in half with adhesive sides together, then dispose of carefully in rubbish.

Monitoring

Use with caution in severe renal or hepatic impairment due to the risk of toxicity.

IV: Continuous ECG monitoring, blood pressure, oxygen saturation, sedation

5% Patch: Pain score and skin irritation. Stop if no benefits after 2 – 4 weeks.

Pregnancy

1st Trimester: Safe to use

2nd Trimester: Safe to use

3rd Trimester: Safe to use

Breastfeeding

Safe to use

Related Policies, Procedures & Guidelines

HDWA Mandatory Policies:

WNHS Clinical Practice Guidelines:

Lidocaine (lignocaine) infusion: Intravenous

Operative Vaginal Brith

Neuraxial Analgesia

Anaesthesia and Pain Management

WNHS Pharmaceutical and Medicines Management Guidelines:

SASA Lidocaine (Lignocaine)

References

AusDI. Lidocaine (Topical). In: AusDI [Internet]. Telstra Health: AusDI; [cited 2025 Mar 27]. Available from: Lidocaine (Topical) - AusDI (health.wa.gov.au)

Australian Medicines Handbook. Lidocaine (anaesthesia). In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2025 [cited 2025 Mar 27]. Available from: https://amhonline.amh.net.au/

Therapeutic Guidelines. The role of analgesics in chronic noncancer pain. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2023 [cited 2025 Mar 27]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

The Royal Women's Hospital. Lidocaine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2024 [cited 2025 Mar 27]. Available from: https://thewomenspbmg.org.au/

Keywords	Lidocaine, lignocaine, xylocaine®, versatis®, emla®, local anaesthetic, antiarrhythmic, cardiac, analgesia				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	August 2015	Last Reviewed:	May 2025	Review Date:	May 2030
Endorsed by:	Medicines and Therapeutics Committee			Date:	03/06/2025
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance ☐ Std 2: Partnering with Consumers ☐ Std 3: Preventing and Controlling Healthcare Associated Infection ☒ Std 4: Medication Safety			☐ Std 5: Comprehensive Care ☐ Std 6: Communicating for Safety ☐ Std 7: Blood Management ☐ Std 8: Recognising and Responding to Acute Deterioration	
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2025

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.